Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib and TACE for Perioperative Liver Transplantation in HCC
NCT05576909Phase 2Unknown
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Beijing Tsinghua Changgung Hospital. Status: unknown.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05576909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576909.